MicroMM Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation
- Coordinator
- Technische Universitaet Muenchen, Germany
- Runs
- 1 November 2026 to 31 October 2031
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101304230
What the project is doing
In the project's own words, from its summary on CORDIS.
The gut microbiome is a key regulator of human immunity, shaping responses to infection, vaccination, and cancer. Population-level differences in microbiome composition and function have been linked to variable vaccine efficacy, yet the mechanisms remain poorly understood. During defined physiological or clinical windows, the equilibrium between host and microbiome becomes particularly vulnerable, and transient perturbations can durably imprint on immune function and disease risk.
Hematopoietic stem cell transplantation (SCT), a cornerstone therapy for hematologic cancers such as multiple myeloma (MM), represents one such scenario, marked by profound microbiome disruption, immune reconstitution, and the need for re-vaccination. MM patients often mount poor vaccine responses and experience infection-related morbidity. This setting uniquely enables the investigation of host-microbiome-vaccine interactions in a controlled yet physiologically authentic context, offering insights unattainable in healthy adults.
Through MicroMM, I will define how microbiome perturbations during SCT shape immune recovery, vaccine responsiveness, and clinical outcome in MM patients. Leveraging a longitudinal cohort, I will integrate functional microbiome analyses, high-resolution immune profiling, and serial vaccine monitoring, focusing on vaccines with known variability post-SCT. Advanced computational modeling will identify microbiome signatures predictive of vaccine efficacy and immune resilience.
To establish causality, mechanistic studies in gnotobiotic mice colonized with patient-derived microbiomes will dissect microbial contributions to immune imprinting, vaccine performance, and tumor control. By bridging clinical observation with mechanistic experimentation, MicroMM will uncover fundamental principles of microbiome-driven immune modulation and define actionable biomarkers to improve vaccine responsiveness and immune resilience in at-risk populations.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Technische Universitaet Muenchen | Muenchen | Germany | Coordinator |
| Klinikum Der Technischen Universität München (tum Klinikum) | Muenchen | Germany | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI